microdosing glp-1 agonists Drugs: What To Know THE GLP-1 MICRODOSING PROGRAM

Learn what research shows about GLP-1 medications for autoimmune thyroid conditions, safety considerations, and evidence-based treatment options for Hashimoto's thyroiditis.

Background Glucagon-like peptide-1 (GLP-1) induces diuresis and natriuresis

The Fitish RX GLP-1 Microdosing Program is designed for individuals who are not looking for significant weight loss or maintenance dosing, but want subtle, cosmetic support to help reinforce balanced habits and mindful eating

Phase 2 trials showed significant weight loss up to 20% at 52 weeks

The aim of the present review is to examine the cellular processes underlying the actions of these new, highly significant classes of peptide receptor agonists

Gastric inhibitory polypeptide (GIP) and glucagonlike peptide1 (GLP1) are the two primary incretin hormones secreted from the intestine on ingestion of glucose or nutrients to stimulate insulin secretion from pancreatic cells